

# Synthesis and characterisation of 1-alkyl-2-imidazoline complexes of noble metals; crystal structure of *trans*-[PtCl<sub>2</sub>{N=C(H)N(Et)CH<sub>2</sub>CH<sub>2</sub>}(PEt<sub>3</sub>)] \*

Bekir Çetinkaya,<sup>a</sup> Engin Çetinkaya,<sup>a</sup> Peter B. Hitchcock,<sup>b</sup> Michael F. Lappert<sup>b</sup> and İsmail Özdemir<sup>a</sup>

<sup>a</sup> Department of Chemistry, İnönü University, 44280-Malaya, Türkiye

<sup>b</sup> The Chemistry Laboratory, University of Sussex, Brighton BN1 9QJ, UK


Treatment of a 1-alkyl-2-imidazoline  $\overline{\text{N(R)(CH}_2)_2\text{N=CH}}$  with a  $\mu$ -dichloro-dirhodium(i) or -diplatinum(ii) complex  $[\{\text{Rh}(\mu\text{-Cl})(\text{cod})\}_2]$  or  $[\{\text{Pt}(\mu\text{-Cl})\text{Cl}(\text{PEt}_3)\}_2]$  gave the mononuclear 1-alkyl-2-imidazoline complex  $[\text{RhCl}\{\overline{\text{N=C(H)N(R)CH}_2\text{CH}_2}\}(\text{cod})]$  (R = Et **1a** or CH<sub>2</sub>Ph **1b**) or *trans*-[PtCl<sub>2</sub>{ $\overline{\text{N=C(H)N(R)CH}_2\text{CH}_2}$ }(PEt<sub>3</sub>)] (R = Et **2a** or CH<sub>2</sub>Ph **2b**) (cod = cycloocta-1,5-diene). A single-crystal X-ray diffraction study of **2a** revealed it to have a square-planar geometry about platinum, the imidazoline ring being coplanar with this plane, and a Pt–N distance of 2.088(11) Å; the Pt–P bond length of 2.231(4) Å indicates that the imidazoline ligand has a marginally stronger *trans* influence than analogues of its isomer such as  $\overline{\text{CN(R)(CH}_2)_2\text{NR}}$ . The rhodium complexes **1a** and **1b** have been shown to catalyse cyclopropanation of styrene and ethyl diazoacetate in high yields.

The co-ordination chemistry of imidazole and related compounds, including benzimidazoles, benzoxazoles and benzthiazoles, has been extensively studied in part because of their role in aspects of catalysis and biomimetics.<sup>1,2</sup> Since some of these heterocycles are corrosion inhibitors, their metal complexes may also have some relevance to anticorrosion mechanisms.<sup>3</sup> In addition, some have a variety of pharmacological effects, such as antitumour activity; for instance bis(acetato)bis(imidazole)-copper(ii)<sup>4,5</sup> and imidazolium tetrachlorobis(imidazole)ruthenate(iii)<sup>6</sup> were reported to be highly active antagonists toward tumour models. The presence of planar nitrogen-centred ligands L in *trans*-[PtCl<sub>2</sub>L<sub>2</sub>] often appeared to enhance their cytotoxicity relative to the corresponding *cis* isomer or to *cis*-[PtCl<sub>2</sub>(NH<sub>3</sub>)<sub>2</sub>].<sup>7</sup>

Imidazole and its derivatives are bound through N<sup>3</sup> of the imidazole ring.<sup>8,9</sup> However, conversion of an imidazolemetal complex into the isomeric (imidazolium ylide)metal complex, having a C<sup>2</sup>–M bond, has been described.<sup>10</sup> In contrast, results on the related chemistry of 1-alkyl-4,5-dihydroimidazoles, the *N*-(or 1-alkyl)-2-imidazolines, are as yet much more sparse. At the outset of this work the only previous studies had been concerned with the bidentate imidazoline complexes of some late first-row transition metals.<sup>11,12</sup> Recently, the reaction of 2-phenylimidazoline with some palladium(ii) complexes yielding cyclometallated products was described.<sup>13</sup>

In 1977 we reported that an attempt at an *in situ* synthesis of an NH-substituted imidazolidin-2-ylidene(or carbene)molybdenum(0) complex **I**, containing an Mo{ $\overline{\text{CN(R)(CH}_2)_2\text{NH}}$ } moiety, from [Mo(CO)<sub>6</sub>], CH(OMe)<sub>2</sub>NMe<sub>2</sub> and H<sub>2</sub>N(CH<sub>2</sub>)<sub>2</sub>NHR led instead to the isomeric *N*-bonded 2-imidazoline-molybdenum(0) complexes **II**;<sup>14</sup> the latter were also accessible from [Mo(CO)<sub>6</sub>] and  $\overline{\text{N(R)(CH}_2)_2\text{N=CH}}$  (R = H or Et) as was  $[\text{RhCl}\{\overline{\text{N=C(H)N(R)CH}_2\text{CH}_2}\}(\text{cod})]$  from  $[\{\text{Rh}(\mu\text{-Cl})(\text{cod})\}_2]$  and  $\overline{\text{N(R)(CH}_2)_2\text{N=CH}}$  (cod = cycloocta-1,5-diene). The present paper reports an extension of these experiments.

A further reason for our pursuing the present study is that the imidazoline complexes  $[\text{RhCl}\{\overline{\text{N=C(H)N(R)CH}_2\text{CH}_2}\}(\text{cod})]$  (R = Et **1a** or CH<sub>2</sub>Ph **1b**) showed significant selective anti-



bacterial activity<sup>15</sup> and were effective catalysts for cyclisation of (*Z*)-3-methylpent-2-en-4-yn-1-ol into 2,3-dimethylfuran.<sup>16</sup>

In this paper we describe the synthesis, isolation and spectroscopic characterisation of four new 1-alkyl-2-imidazoline complexes of rhodium(i) (**1a** and **1b**) and platinum(ii) (**2a** and **2b**) derived from the imidazoline  $\overline{\text{N(R)(CH}_2)_2\text{N=CH}}$  (R = Et or CH<sub>2</sub>Ph) and the molecular structure of *trans*-[PtCl<sub>2</sub>{ $\overline{\text{N=C(H)N(Et)CH}_2\text{CH}_2}$ }(PEt<sub>3</sub>)] **2a**, which we believe provides the first such data on a 1-alkyl-2-imidazolineplatinum(ii) complex. The complexes **1a** and **1b** were shown to be effective catalysts for a cyclopropanation reaction.


## Results and Discussion

An enetetramine  $[\overline{\text{=CN(R)(CH}_2)_2\text{NR}}]_2$  (abbreviated as L<sup>R</sup><sub>2</sub>) has been shown to behave as a C-centred nucleophile in readily cleaving a di- $\mu$ -dichloro-dimetal complex such as  $[\{\text{Rh}(\mu\text{-Cl})(\text{cod})\}_2]$  **A** or  $[\{\text{Pt}(\mu\text{-Cl})\text{Cl}(\text{PEt}_3)\}_2]$  **B** to give the imidazolidin-2-ylidene(or carbene)metal complex  $[\text{RhCl}(\text{cod})(\text{L}^{\text{R}})]$  or  $[\text{PtCl}_2(\text{L}^{\text{R}})(\text{PEt}_3)]$ .<sup>17</sup> A similar approach was used in the present study. Thus, 2 equivalents of the imidazoline  $\overline{\text{N(R)(CH}_2)_2\text{N=CH}}$  (R = Et or CH<sub>2</sub>Ph) were heated with **A** or **B** affording the appropriate mononuclear 1-alkyl-2-imidazoline-rhodium(i) **1** or -platinum(ii) **2** complex in good yield (Table 1), Scheme 1 [(i) or (ii)].

Each of the complexes **1a**, **1b**, **2a** and **2b** was obtained in moderate to high yield as air-stable crystals, which were characterised by elemental analysis and IR (Table 1), <sup>1</sup>H NMR (Table 2) and <sup>13</sup>C-<sup>1</sup>H NMR (Table 3) spectra; the tables also include corresponding data on the imidazolines  $\overline{\text{N(R)(CH}_2)_2\text{N=CH}}$  [R = Et (an oil at ambient temperature) or CH<sub>2</sub>Ph] which were reported briefly.<sup>18</sup>

\* Non-SI unit employed: mmHg  $\approx$  133 Pa.

The IR spectra of each of the four complexes showed an intense absorption band at  $1605 \pm 12 \text{ cm}^{-1}$  assigned to  $\nu(\text{C}=\text{N})$  which decreased in frequency relative to the free imidazolines in the case of **1a** and **1b**, while for **2a** and **3b** the opposite was the case, which may be because the ligand in the last two complexes is *trans* to a tertiary phosphine rather than an alkene, as in **1a** or **1b**.



**Scheme 1** Routes to 1-alkyl-2-imidazoline complexes **1** and **2**: (i)  $[\{\text{Rh}(\mu\text{-Cl})(\text{cod})\}_2]$  (0.5 equivalent), toluene,  $110^\circ\text{C}$ , 2 h; (ii)  $[\{\text{Pt}(\mu\text{-Cl})\text{Cl}(\text{PEt}_3)\}_2]$  (0.5 equivalent), toluene,  $110^\circ\text{C}$ , 2 h

The  $^1\text{H}$  NMR spectral chemical shifts of the metal-bound imidazolines in complexes **1b** and **2b** were found at higher frequency than in the free imidazoline, but the effect was least obvious for the CH<sub>2</sub> protons and was not as marked as in the related imidazole complexes,<sup>19</sup> perhaps due to the aromaticity of the imidazole ligands. The variations in the  $^{13}\text{C}$  NMR chemical shifts as between **1b** and **2b** on the one hand, and the free imidazoline on the other, were less pronounced.

The  $^{13}\text{C}\{-^1\text{H}\}$  NMR spectra were particularly diagnostic as to the nature of the bonding in these new complexes, establishing them to be N<sup>3</sup>-bound 2-imidazolines rather than C<sup>2</sup>-bound imidazolidin-2-ylidenes. Thus, the imino N=CH signal was observed as a singlet at  $\delta$  161.3 for  $[\text{RhCl}\{\text{N}=\text{C}(\text{H})\text{N}(\text{CH}_2\text{Ph})\text{CH}_2\text{CH}_2\}(\text{cod})]$  **1b**, but a doublet centred at  $\delta$  158.4 for *trans*- $[\text{PtCl}_2\{\text{N}=\text{C}(\text{H})\text{N}(\text{CH}_2\text{Ph})\text{CH}_2\text{CH}_2\}(\text{PEt}_3)]$  **2b**,  $^4J(^{13}\text{C}\text{-}^{31}\text{P}) = 2 \text{ Hz}$ . By contrast, in  $\text{Rh}^{\text{I}}\text{-L}^{\text{R}}$  or  $\text{Pt}^{\text{II}}\text{-L}^{\text{R}}$  complexes, the carbene carbon atom showed a large  $^{13}\text{C}\text{-}^{103}\text{Rh}$  or  $^{13}\text{C}\text{-}^{195}\text{Pt}$  coupling constant, *e.g.*  $^1J(^{13}\text{C}\text{-}^{103}\text{Rh})$  in the range 38–65 Hz.<sup>20</sup>

The  $^{31}\text{P}\{-^1\text{H}\}$  NMR spectra of complexes **2a** and **2b** showed singlets at  $\delta$  1.12 and 0.71 with  $^{195}\text{Pt}$  satellites,  $^1J(^{31}\text{P}\text{-}^{195}\text{Pt}) = 3345$  and  $3314.1 \text{ Hz}$ , respectively.

**Table 1** Yields, melting points, IR<sup>a</sup> and analytical data for the new compounds

Compound	Yield (%)	M.p. ( $^\circ\text{C}$ ) [b.p. ( $^\circ\text{C}$ , mmHg)]	$\nu(\text{C}=\text{N})^a/cm^{-1}$	Analysis (%) <sup>b</sup>		
				C	H	N
$\text{N}(\text{Et})(\text{CH}_2)_2\text{N}=\text{CH}$	90	[44–46, 0.5]	1605			
$\text{N}(\text{CH}_2\text{Ph})(\text{CH}_2)_2\text{N}=\text{CH}$	84	39–40	1605	75.5 (75.0)	7.15 (7.5)	17.7 (17.5)
<b>1a</b>	95	112–113	1595	55.7 (54.4)	6.5 (6.0)	6.0 (6.7)
<b>1b</b>	72	120–121	1593	45.4 (45.3)	5.95 (6.4)	8.95 (8.15)
<b>2a</b>	62	92–93	1610	27.4 (26.9)	5.2 (5.25)	5.8 (6.15)
<b>2b</b>	88	103–104	1616	35.3 (34.9)	4.95 (4.8)	5.15 (5.7)

<sup>a</sup> As KBr discs. <sup>b</sup> Calculated values in parentheses.

**Table 2** Proton NMR chemical shifts ( $\delta$ ) and coupling constants ( $J/\text{Hz}$ )

Compound	Ring		Others
	C <sup>2</sup> H	4,5-CH <sub>2</sub>	
$\text{N}(\text{Et})(\text{CH}_2)_2\text{N}=\text{CH}$	6.76 (s)	2.85 (m), 3.66 (m)	0.96 (t, $J = 7.0$ , $\text{CH}_2\text{CH}_3$ ), 2.85 (q, $J = 6.0$ , $\text{CH}_2\text{CH}_3$ )
$\text{N}(\text{CH}_2\text{Ph})(\text{CH}_2)_2\text{N}=\text{CH}$	6.70 (s)	2.70 (m), 3.70 (m)	3.67 (s, $\text{CH}_2\text{C}_6\text{H}_5$ ), 7.1 (m, $\text{CH}_2\text{C}_6\text{H}_5$ )
<b>1a</b>	7.61 (s)	3.30 (t, $J = 11.4$ ), 3.47 (t, $J = 11.4$ )	1.1 (t, $J = 7.25$ , $\text{CH}_2\text{CH}_3$ ), 1.69 (d, $J = 4.9$ ), 2.23 (d, $J = 7.4$ , cod CH <sub>2</sub> ), 3.14 (q, $J = 7.25$ , $\text{CH}_2\text{CH}_3$ ), 3.79 (s) and 4.37 (s) (cod C=H)
<b>1b</b>	7.83 (s)	3.20 (t, $J = 10.7$ ), 3.51 (t, $J = 10.7$ )	1.73 (d, $J = 8.6$ ), 2.39 (d, $J = 4.9$ , cod CH <sub>2</sub> ), 3.82 (s) and 4.44 (s) (cod C=H), 4.29 (s, $\text{CH}_2\text{C}_6\text{H}_5$ ), 7.30 (m, $\text{CH}_2\text{C}_6\text{H}_5$ )
<b>2a</b>	7.56 (s)	3.3 (t, $J = 10.0$ ), 4.0 (t, $J = 10.0$ )	1.0 (t, $J = 7.0$ , $\text{CH}_2\text{CH}_3$ ), 1.19 (t, $J = 7.6$ , $\text{PCH}_2\text{CH}_3$ ), 1.80 (q, $J = 7.6$ , $\text{PCH}_2\text{CH}_3$ ), 3.2 (q, $J = 7.0$ , $\text{CH}_2\text{CH}_3$ )
<b>2b</b>	7.78 (s)	3.3 (t, $J = 10.4$ ), 4.07 (t, $J = 10.4$ )	1.20 (t, $J = 7.6$ , $\text{PCH}_2\text{CH}_3$ ), 1.80 (q, $J = 7.6$ , $\text{PCH}_2\text{CH}_3$ ), 4.33 (s, $\text{CH}_2\text{C}_6\text{H}_5$ ), 7.32 (m, $\text{CH}_2\text{C}_6\text{H}_5$ )

**Table 3**  $^{13}\text{C}\{-^1\text{H}\}$  NMR chemical shifts ( $\delta$ ) and coupling constants ( $J/\text{Hz}$ )

Compound	Ring		Others
	C <sup>2</sup> H	4,5-CH <sub>2</sub>	
$\text{N}(\text{Et})(\text{CH}_2)_2\text{N}=\text{CH}$	157.2	42.3, 48.6	14.1 ( $\text{CH}_2\text{CH}_3$ ), 55.8 ( $\text{CH}_2\text{CH}_3$ )
$\text{N}(\text{CH}_2\text{Ph})(\text{CH}_2)_2\text{N}=\text{CH}$	157.2	48.6, 52.0	56.1 ( $\text{CH}_2\text{C}_6\text{H}_5$ ), 127.6, 128.2, 128.9 ( $\text{CH}_2\text{C}_6\text{H}_5$ )
<b>1a</b>	161.1	30.2, 31.6	13.6 ( $\text{CH}_2\text{CH}_3$ ), 41.8, 47.4 (cod CH <sub>2</sub> ), 50.7 ( $\text{CH}_2\text{CH}_3$ ), 75.0 (d, $J = 14.4$ ) and 81.8 (d, $J = 11.7$ ) (cod CH)
<b>1b</b>	161.3	47.2, 50.9	30.1, 31.4 (cod CH <sub>2</sub> ), 51.3 ( $\text{CH}_2\text{C}_6\text{H}_5$ ), 75.1 (d, $J = 13.0$ ) and 81.9 (d, $J = 11.0$ ) (cod CH), 127.7, 128.1, 128.8, 134.8 ( $\text{CH}_2\text{C}_6\text{H}_5$ )
<b>2a</b>	157.7	47.1, 50.7	7.4 (d, $J = 3.1$ , $\text{PCH}_2\text{CH}_3$ ), 12.1 ( $\text{CH}_2\text{CH}_3$ ), 13.8 (d, $J = 39.4$ , $\text{PCH}_2\text{CH}_3$ ), 41.7 ( $\text{CH}_2\text{CH}_3$ )
<b>2b</b>	158.4	47.4, 51.2	7.6 (d, $J = 3.0$ , $\text{PCH}_2\text{CH}_3$ ), 13.9 (d, $J = 39.0$ , $\text{PCH}_2\text{CH}_3$ ), 51.6 ( $\text{CH}_2\text{C}_6\text{H}_5$ ), 127.8, 128.1, 128.8, 134.8 ( $\text{CH}_2\text{C}_6\text{H}_5$ )




Fig. 1 Structure of *trans*-[PtCl<sub>2</sub>{N=C(H)N(Et)CH<sub>2</sub>CH<sub>2</sub>}(PEt<sub>3</sub>)] **2a**

Table 4 Selected bond lengths (Å) and angles (°) with estimated standard deviations in parentheses for *trans*-[PtCl<sub>2</sub>{N=C(H)N(Et)CH<sub>2</sub>CH<sub>2</sub>}(PEt<sub>3</sub>)] **2a**


Pt–Cl(1)	2.283(4)	Pt–Cl(2)	2.291(5)
Pt–P	2.231(4)	Pt–N(1)	2.088(11)
P–C(6)	1.82(2)	P–C(8)	1.85(2)
P–C(10)	1.83(2)	N(1)–C(1)	1.29(2)
N(1)–C(3)	1.57(2)	N(2)–C(1)	1.33(2)
N(2)–C(2)	1.48(2)	N(2)–C(4)	1.41(2)
C(2)–N(3)	1.51(3)	C(4)–C(5)	1.52(2)
C(6)–C(7)	1.53(3)	C(8)–C(9)	1.56(2)
C(10)–C(11)	1.52(3)		
Cl(1)–Pt–Cl(2)	178.6(2)	Cl(1)–Pt–P	88.7(2)
Cl(1)–Pt–N(1)	88.6(3)	Cl(2)–Pt–P	92.5(2)
Cl(2)–Pt–N(1)	90.2(3)	P–Pt–N(1)	177.0(3)
Pt–P–C(6)	116.1(5)	Pt–P–C(8)	114.1(5)
Pt–P–C(10)	110.7(5)	C(6)–P–C(8)	105.3(7)
C(6)–P–C(10)	106.6(8)	C(8)–P–C(10)	102.9(7)
Pt–N(1)–C(1)	128.1(9)	Pt–N(1)–C(3)	124.8(9)
C(1)–N(1)–C(3)	107(1)	C(1)–N(2)–C(2)	109(1)
C(1)–N(2)–C(4)	125(1)	C(2)–N(2)–C(4)	124(1)
N(1)–C(1)–N(2)	116(1)	N(2)–C(2)–C(3)	104(1)
N(1)–C(3)–C(2)	103(1)	N(2)–C(4)–C(5)	116(1)
P–C(6)–C(7)	116(1)	P–C(8)–C(9)	111(1)
P–C(10)–C(11)	112(1)		

Single crystals of complex **2a** were grown from CH<sub>2</sub>Cl<sub>2</sub>–Et<sub>2</sub>O at ambient temperature. The molecular structure is shown in Fig. 1 and selected bond lengths and angles are given in Table 4. The platinum is in a square-planar environment, with the chlorides *trans* to one another. The Pt–Cl [average 2.287(4) Å] and Pt–P [2.231(4) Å] bond lengths may be compared with those in *trans*-[PtCl<sub>2</sub>(L<sup>Ph</sup>)(PEt<sub>3</sub>)] **III** [L<sup>Ph</sup> = CN(Ph)(CH<sub>2</sub>)<sub>2</sub>NPh]; Pt–Cl 2.301(6) (average) and Pt–P 2.291(4) Å].<sup>21</sup> Hence it appears that the *trans* influence of the 1-ethyl-2-imidazoline ligand in **2a** is slightly greater than that of the carbene (or imidazolidin-2-ylidene) ligand L<sup>Ph</sup> in **III**.

For the cyclopropanation of alkanes with diazo compounds various efficient transition-metal catalysts have been reported. Although those available have proved useful in many instances, the search for alternatives goes on. Recently, bis(2-oxazolin-2-yl)(pyridine)ruthenium(II) complexes have been introduced as efficient cyclopropanation catalysts, which give good *trans*–*cis* selectivities.<sup>22</sup> Hence, we have checked the new rhodium(I) compounds **1a** and **1b** in the same context (Scheme 2). With 0.9 mol % catalyst at 80 °C styrene gave an excellent yield (91–95%) of the cyclopropanation product with ethyl diazoacetate. The mechanistic details of this catalytic reaction are currently under investigation.

## Experimental

Unless otherwise stated, manipulations were carried out under argon using a high-vacuum manifold and conventional Schlenk techniques. Solvents were distilled over appropriate drying agents and thoroughly degassed prior to use. The complexes [{Rh(μ-Cl)(cod)}<sub>2</sub>]<sup>23</sup> and [{Pt(μ-Cl)Cl(PEt<sub>3</sub>)<sub>2</sub>]<sup>24</sup> were



Scheme 2 (i) Rhodium(I) complex **1a** or **1b**

prepared by published methods. The 1-alkyl-2-imidazolines N(R)(CH<sub>2</sub>)<sub>2</sub>N=CH (R = Et or CH<sub>2</sub>Ph) were readily prepared from CH(OMe)<sub>2</sub>NMe<sub>2</sub> and the appropriate diamine H<sub>2</sub>N–(CH<sub>2</sub>)<sub>2</sub>NHR.<sup>18</sup>

The IR spectra were recorded as samples in KBr discs or as Nujol mulls on a Unicam 2100 grating spectrophotometer, NMR spectra, for samples in CDCl<sub>3</sub> solution, on a Bruker WM 360 or AC-250SY instrument. Elemental analyses were obtained in the Middle East Technical University, Ankara.

## Preparations

**1-Ethyl-2-imidazoline.** A solution of *N*-ethylethane-1,2-diamine (12.55 g, 124 mmol) and CH(OMe)<sub>2</sub>NMe<sub>2</sub> (19.06 g, 160 mmol) was slowly heated. When the oil-bath temperature reached 75–80 °C, NMe<sub>2</sub>H and MeOH began to distil off. The brown residue was distilled at 34–36 °C (0.4 mmHg) to obtain a colourless liquid.

**1-Benzyl-2-imidazoline.** A solution of *N*-benzylethane-1,2-diamine (2.0 g, 13.3 mmol) in cyclohexane (4 cm<sup>3</sup>) was added to CH(OMe)<sub>2</sub>NMe<sub>2</sub> (1.29 g, 15 mmol) and the mixture was heated under distillation conditions, allowing the produced NMe<sub>2</sub>H and MeOH to distil off. Then volatiles were removed under vacuum. The residue (1.79 g) was crystallised from toluene (1.5 cm<sup>3</sup>)–hexane (6 cm<sup>3</sup>).

### (1-Alkyl-2-imidazoline)chloro(cycloocta-1,5-diene)rhodium(I)

**1a and 1b.** A solution of 1-ethyl-2-imidazoline (0.16 g, 1.6 mmol) in toluene (15 cm<sup>3</sup>) and [{Rh(μ-Cl)(cod)}<sub>2</sub>] (0.40 g, 0.80 mmol) was heated for 2 h under reflux. Hexane (5 cm<sup>3</sup>) was added to the warm solution. Upon cooling to room temperature yellow-orange crystals of complex **1a** (0.47 g) were filtered off, washed with cold hexane (2 × 5 cm<sup>3</sup>) and dried in a vacuum.

Similarly, from the same rhodium(I) starting material (0.60 g, 1.21 mmol) and 1-benzyl-2-imidazoline (0.38 g, 2.43 mmol), orange crystals of complex **1b** (0.89 g) were obtained.

**trans-(1-Alkyl-2-imidazoline)dichloro(triethylphosphine)platinum(II) 2a and 2b.** A solution of 1-ethyl-2-imidazoline (0.14 g, 1.43 mmol) in toluene (10 cm<sup>3</sup>) was added to [{Pt(μ-Cl)Cl(PEt<sub>3</sub>)<sub>2</sub>}] (0.56 g, 0.73 mmol) and the mixture was heated for 2 h under reflux. Upon addition of hexane (6 cm<sup>3</sup>) to the resulting yellow solution and cooling to room temperature, yellow crystals of complex **2a** (0.48 g) were filtered off, washed with hexane (2 × 10 cm<sup>3</sup>) and dried under vacuum.

Yellow microcrystals of compound **2b** (0.56 g) were obtained similarly from 1-benzyl-2-imidazoline (0.20 g, 1.25 mmol) and the same platinum(II) starting material (0.50 g, 0.65 mmol).

## Cyclopropanation reactions

In a typical experiment, the catalyst **1** (0.009 mmol) and styrene (20 mmol, 2.3 cm<sup>3</sup>) were introduced into a Schlenk tube and then ethyl diazoacetate (1 mmol) in styrene (1 cm<sup>3</sup>) was added. The mixture was stirred in an oil-bath at 80 °C for 4 h. The yields and the ratio of isomers were determined by GC.

## Crystallography

**Crystal data.** C<sub>11</sub>H<sub>25</sub>Cl<sub>2</sub>N<sub>2</sub>PPt, *M* = 482.3, tetragonal, space group *I*<sub>4</sub> (no. 82), *a* = *b* = 20.997(2), *c* = 7.549(1) Å, *U* = 3327.9 Å<sup>3</sup>, *Z* = 8, *D*<sub>c</sub> = 1.93 g cm<sup>−3</sup>, *F*(000) = 1856, μ(Mo–Kα) = 89.2 cm<sup>−1</sup>, 293 K.

**Data collection, structure solution and refinement.** X-Ray diffraction data were collected on a crystal of dimensions  $0.3 \times 0.2 \times 0.2$  mm, in a Lindemann capillary sealed under argon, on an Enraf-Nonius CAD4 diffractometer in the  $\theta$ - $2\theta$  mode with a scan width of  $\Delta\theta = (0.8 + 0.35 \tan \theta)^\circ$ , maximum scan time of 1 min and Mo-K $\alpha$  radiation ( $\lambda = 0.71069$  Å). A total of 1112 unique reflections was measured for  $2 < \theta < 22^\circ$  and  $+h +k +l$ ; 1010 reflections with  $|F^2| > 3\sigma(F^2)$ , where  $\sigma(F^2) = [\sigma^2(I) + (0.04I)^2]/L_p$ , were used in the refinement. There was no crystal decay during the data collection. A correction (maximum 1.22, minimum 0.85) for absorption was applied using DIFABS<sup>25</sup> after isotropic refinement.

The structure was solved using the heavy-atom routines of SHELX 86<sup>26</sup> and non-hydrogen atoms were refined on  $F$  with anisotropic thermal parameters by full-matrix least squares. Hydrogen atoms were held at calculated positions with  $U_{iso} = 1.3U_{eq}$  for the parent atom. Final parameters were  $R = 0.026$ ,  $R' = 0.033$ ,  $S = 1.26$ , 154 variables,  $w = 1/\sigma^2(F)$ ,  $(\Delta/\sigma)_{max} = 0.01$  and  $(\Delta\rho)_{max,min} = +0.57, -0.65$  e Å<sup>-3</sup> on a final difference map. Programs from the SDP-PLUS package<sup>27</sup> were run on a Micro Vax II computer.

Atomic coordinates, thermal parameters, and bond lengths and angles have been deposited at the Cambridge Crystallographic Data Centre (CCDC). See Instructions for Authors, *J. Chem. Soc., Dalton Trans.*, 1997, Issue 1. Any request to the CCDC for this material should quote the full literature citation and the reference number 186/428.

## Acknowledgements

We thank Professor P. H. Dixneuf for helpful discussions, the Leverhulme Trustees for an Emeritus Fellowship (for M. F. L.) and the EPSRC for support.

## References

- 1 A. L. Abuhijleh, *Polyhedron*, 1996, **15**, 285.
- 2 K. Nonoyama, W. Mori and M. Nonoyama, *Polyhedron*, 1994, **13**, 891; S. Bennett, S. M. Brown, G. Conole, M. Kessler, S. Rowling, E. Sinn and S. Woodward, *J. Chem. Soc., Dalton Trans.*, 1995, 367.
- 3 G. Xue, Q. Dai and S. Jiang, *J. Am. Chem. Soc.*, 1988, **110**, 2393; G. Xue, S. Jiang, X. Huang, G. Shi and B. Sun, *J. Chem. Soc., Dalton Trans.*, 1988, 1487.

- 4 J. R. J. Sorrenson, *Prog. Med. Chem.*, 1989, **26**, 437.
- 5 H. Tamura, H. Imai, J. Kuwahara and Y. Sugiura, *J. Am. Chem. Soc.*, 1987, **109**, 6870.
- 6 A. Galeano, M. R. Berger and B. K. Keppler, *Arzneim.-Forsch., Drug Res.*, 1992, **42**, 821.
- 7 M. van Beusichem and N. Farrell, *Inorg. Chem.*, 1992, **31**, 634.
- 8 R. J. Sundberg, R. F. Bryan, I. F. Taylor and H. Taube, *J. Am. Chem. Soc.*, 1974, **96**, 381.
- 9 J. Müller and R. Stock, *Angew. Chem., Int. Ed. Engl.*, 1983, **22**, 993.
- 10 F. Bonati, L. A. Oro, M. T. Pinillos and C. Tejel, *J. Organomet. Chem.*, 1994, **465**, 267.
- 11 S. S. Tandon, L. K. Thompson, J. N. Bridson and J. C. Dewan, *Inorg. Chem.*, 1994, **33**, 54 and refs. therein.
- 12 J. Bremer, S. Uhlenbrock, A. A. Pinkerton and B. Krebs, *Z. Anorg. Allg. Chem.*, 1993, **619**, 1183.
- 13 C. Navarro-Ranninger, F. Zamora, I. López-Solera, A. Monge and J. R. Masaguer, *J. Organomet. Chem.*, 1996, **506**, 149.
- 14 P. B. Hitchcock, M. F. Lappert and P. L. Pye, *J. Chem. Soc., Dalton Trans.*, 1977, 2160.
- 15 B. Çetinkaya, E. Çetinkaya, H. Küçükbay and R. Durmaz, *Arzneim.-Forsch., Drug Res.*, 1996, **46**, 821.
- 16 B. Çetinkaya, I. Özdemir, C. Bruneau and P. H. Dixneuf, unpublished work.
- 17 M. F. Lappert, *J. Organomet. Chem.*, 1988, **358**, 185.
- 18 E. Çetinkaya and M. F. Lappert, *Chemistry and Chemical Engineering Symposium, Abstracts, Kusadası*, 1989, p. 140.
- 19 F. Bonati, L. A. Oro, M. T. Pinillos, C. Tejel, M. C. Aprea, C. Foces-Foces and F. H. Cano, *J. Organomet. Chem.*, 1989, **369**, 253.
- 20 B. Çetinkaya, P. B. Hitchcock, M. F. Lappert, D. B. Shaw, K. Spyropoulos and N. J. W. Warhurst, *J. Organomet. Chem.*, 1993, **459**, 311.
- 21 L. Manojlović-Muir and K. W. Muir, *J. Chem. Soc., Dalton Trans.*, 1974, 2427.
- 22 S.-B. Park, N. Sakata and H. Nishiyama, *Chem. Eur. J.*, 1996, **3**, 303; H. Nishiyama, Y. Itoh, Y. Sugawara, H. Matsumoto, K. Aoki and K. Itoh, *Bull. Chem. Soc. Jpn.*, 1995, **68**, 1247.
- 23 J. Chatt and L. M. Venanzi, *J. Chem. Soc.*, 1957, 4735.
- 24 J. Chatt and L. M. Venanzi, *J. Chem. Soc.*, 1957, 2351.
- 25 N. Walker and D. Stuart, *Acta Crystallogr., Sect. A.*, 1983, **39**, 158.
- 26 G. M. Sheldrick, SHELXS 86, Program for the Solution of Crystal Structure Refinement, University of Göttingen, 1986.
- 27 SDP-PLUS, Enraf-Nonius, Delft, 1978.

Received 12th December 1996; Paper 6/08360I